...
首页> 外文期刊>Oncology Research >Epidermal growth factor-responsive laryngeal squamous cancer cell line Hep2 is more sensitive than unresponsive CO-K3 one to quercetin and tamoxifen apoptotic effects.
【24h】

Epidermal growth factor-responsive laryngeal squamous cancer cell line Hep2 is more sensitive than unresponsive CO-K3 one to quercetin and tamoxifen apoptotic effects.

机译:表皮生长因子反应性喉鳞状细胞癌细胞系Hep2比槲皮素和他莫昔芬的凋亡效应比无反应的CO-K3敏感性更高。

获取原文
获取原文并翻译 | 示例
           

摘要

Epidermal growth factor receptor (EGFR) plays a role in laryngeal squamous cell carcinoma (SCC) development and progression. The flavonoid quercetin (Q) and the antiestrogen tamoxifen (TAM) inhibit proliferation of both primary laryngeal SCC and laryngeal carcinoma cell lines, through still uncharacterized mechanisms. We studied Q and TAM inhibitory effect on epidermal growth factor (EGF)-stimulated Hep2 and CO-K3 laryngeal squamous cell lines. Q and TAM (0.1-1.0 microM) induced more apoptosis in EGF growth-stimulated than in unstimulated Hep2 cells. EGF neither stimulated CO-K3 cell growth nor enhanced Q and TAM-induced apoptosis. Mitogen-activated protein kinase (MAPK) analysis revealed that in Hep2 cells, but not in CO-K3 cells, EGF induced a time-dependent phosphorylation of p42, p44, p38, and p46. In Hep2 cells, but not in CO-K3 cells, Q and TAM produced, upon EGF treatment, a twofold increase of p38 and p46 and an enhancement of p42 and p44 dephosphorylation, suggesting a requirement of EGFR. Theenhancing effect was due to a p38 and p46 dephosphorylation delayed kinetics. An antiphosphorylated p38 antibody prevented Q and TAM inhibitory effect on p42 and p44 phosphorylations, suggesting that the EGF-dependent increase in Q and TAM apoptotic effect on Hep2 cells could depend on the p38 inhibition of the survival kinases p42 and p44. In SCC, EGFR overexpression is an early event from dysplasia to neoplasia. We conclude that the capacity of Q and TAM to increase apoptosis in EGFR-activated cells makes these compounds possible chemopreventive drugs in subjects at risk of developing laryngeal cancer.
机译:表皮生长因子受体(EGFR)在喉鳞状细胞癌(SCC)的发展和进程中起作用。类黄酮槲皮素(Q)和抗雌激素他莫昔芬(TAM)通过仍然未知的机制抑制原发性喉癌SCC和喉癌细胞系的增殖。我们研究了Q和TAM对表皮生长因子(EGF)刺激的Hep2和CO-K3喉鳞状细胞系的抑制作用。 Q和TAM(0.1-1.0 microM)诱导EGF生长刺激比未刺激的Hep2细胞凋亡更多。 EGF既不刺激CO-K3细胞生长,也不增强Q和TAM诱导的细胞凋亡。丝裂原激活的蛋白激酶(MAPK)分析显示,在Hep2细胞中,但在CO-K3细胞中,EGF诱导了p42,p44,p38和p46的时间依赖性磷酸化。 EGF处理后,在Hep2细胞中,但在CO-K3细胞中没有,Q和TAM产生了p38和p46的两倍增加,以及p42和p44的去磷酸化增强,表明需要EGFR。增强作用归因于p38和p46的去磷酸化延迟动力学。抗磷酸化的p38抗体阻止了Q和TAM对p42和p44磷酸化的抑制作用,表明EGF依赖的Q和TAM对Hep2细胞凋亡的作用增加可能取决于对生存激酶p42和p44的p38抑制。在SCC中,EGFR的过度表达是从发育异常到肿瘤形成的早期事件。我们得出的结论是,Q和TAM增加EGFR激活细胞凋亡的能力使这些化合物成为可能发生喉癌的对象的化学预防药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号